Skip to content
Bored Studies
RecruitingPhase 1

Study of BHV-1300 in Graves' Disease

Biohaven Therapeutics Ltd. · NCT06980649

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
15
US sites recruiting
10
Study start
August 21, 2025
Record last updated
July 31, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Being studied: BHV-1300

Conditions: Graves Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Participants must have serologically confirmed Graves' Disease.

Key Exclusion Criteria

  • History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
  • History of treatment with radioactive iodine or thyroid surgery.

Recruiting US locations

Study contacts (from the official record)

  • Chief Medical Officer · 203-404-0410 · clinicaltrials@biohavenpharma.com
All phase 1 studies in California →
Study of BHV-1300 in Graves' Disease (NCT06980649) | Bored Studies